Sign up to our newsletter Subscribe
Health Financing and Pharmaceutical Policy Reform in the Countries of Central and Eastern Europe
Cell and Gene Therapies
Cell and gene therapies offer substantial therapeutic benefits but are expensive and often have a limited evidence base at launch. There are concerns over affordability and long-term cost-effectiveness, as well as uncertainty as to whether their value is accurately captured by current HTA methods.
No posts found